AMBU-B Stock Analysis: Ambu | CO
Medical Devices | CO, Denmark | Market Cap: 17.151m DKK | 12M Return: -24.7% | DK0060946788 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 54.0M
EPS Trend: 72.4%
Qual. Beats: 0
Rev. Trend: 97.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ambu A/S is a Danish medical technology company that researches, develops, manufactures, markets, and sells healthcare equipment and solutions across North America, Europe, and international markets. Its product portfolio spans several clinical areas: endoscopy (including single-use bronchoscopes, laryngoscopes, and other scopes), neurology (EEG/EMG electrodes and intraoperative monitoring), cardiology (ECG electrodes), airway management and anaesthesia (tubes, masks, breathing bags, resuscitators), and emergency care and training products (such as extrication collars and training manikins).
The company is headquartered in Ballerup, Denmark, and was founded in 1937, giving it nearly a century of operating history in the medical device industry. As a player in the healthcare equipment sector, Ambu is positioned to benefit from the broader industry trend toward single-use disposable endoscopy devices, which aim to reduce cross-contamination risk and eliminate the need for device reprocessing between procedures.
- Single-use endoscopy volume growth offsets reusable market competition
- China market softness pressures revenue and gross margins
- FDA single-use duodenoscope mandates support U.S. visualization sales
| Net Income: 510.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.20 > 1.0 |
| NWC/Revenue: 31.44% < 20% (prev 32.38%; Δ -0.94% < -1%) |
| CFO/TA 0.12 > 3% & CFO 941.0m > Net Income 510.0m |
| Net Debt (408.0m) to EBITDA (1.09b): 0.37 < 3 |
| Current Ratio: 2.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (266.6m) vs 12m ago -0.31% < -2% |
| Gross Margin: 56.04% > 18% (prev 59.94%; Δ -3.90% > 0.5%) |
| Asset Turnover: 82.22% > 50% (prev 80.56%; Δ 1.67% > 0%) |
| Interest Coverage Ratio: 9.89 > 6 (EBIT TTM 702.0m / Interest Expense TTM 71.0m) |
| A: 0.25 (Total Current Assets 3.07b - Total Current Liabilities 1.11b) / Total Assets 7.78b |
| B: 0.76 (Retained Earnings 5.89b / Total Assets 7.78b) |
| C: 0.09 (EBIT TTM 702.0m / Avg Total Assets 7.59b) |
| D: 3.84 (Book Value of Equity 6.17b / Total Liabilities 1.61b) |
| Altman-Z'' = 8.78 = AAA |
| DSRI: 1.13 (Receivables 1.05b/882.0m, Revenue 6.24b/5.96b) |
| GMI: 1.07 (GM 59.94% / 56.04%) |
| AQI: 0.96 (AQ_t 0.44 / AQ_t-1 0.46) |
| SGI: 1.05 (Revenue 6.24b / 5.96b) |
| TATA: -0.06 (NI 510.0m - CFO 941.0m) / TA 7.78b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at DKK 68.20 with a total of 406,020 shares traded. Over the past week, the price has changed by +3.73%, over one month by -13.01%, over three months by +11.80% and over the past year by -24.74%.
Current recommended Stop Loss: 65.70 (which is 3.7% or 1.2 ATR below the current price).
Ambu has no consensus analysts rating.
P/E Trailing = 34.2448
P/E Forward = 22.2717
P/S = 2.75
P/B = 2.7701
P/EG = 2.8489
Revenue TTM = 6.24b DKK
EBIT TTM = 702.0m DKK
EBITDA TTM = 1.09b DKK
Long Term Debt = 17.0m DKK (from longTermDebt, two quarters ago)
Short Term Debt = 87.0m DKK (from shortTermDebt, last quarter)
Debt = 1.11b DKK (from shortLongTermDebtTotal, last quarter) + Leases 534.0m
Net Debt = 408.0m DKK (calculated: Debt 1.11b - CCE 705.0m)
Enterprise Value = 17.6b DKK (17.2b + Debt 1.11b - CCE 705.0m)
Interest Coverage Ratio = 9.89 (Ebit TTM 702.0m / Interest Expense TTM 71.0m)
EV/FCF = 27.31x (Enterprise Value 17.6b / FCF TTM 643.0m)
FCF Yield = 3.66% (FCF TTM 643.0m / Enterprise Value 17.6b)
FCF Margin = 10.31% (FCF TTM 643.0m / Revenue TTM 6.24b)
Net Margin = 8.18% (Net Income TTM 510.0m / Revenue TTM 6.24b)
Gross Margin = 56.04% ((Revenue TTM 6.24b - Cost of Revenue TTM 2.74b) / Revenue TTM)
Gross Margin QoQ = 59.45% (prev 60.27%)
Tobins Q-Ratio = 2.26 (Enterprise Value 17.6b / Total Assets 7.78b)
Interest Expense / Debt = 6.38% (Interest Expense 71.0m / Debt 1.11b)
Taxrate = 23.08% (153.0m / 663.0m)
NOPAT = 540.0m (EBIT 702.0m * (1 - 23.08%))
Current Ratio = 2.77 (Total Current Assets 3.07b / Total Current Liabilities 1.11b)
Debt / Equity = 0.18 (Debt 1.11b / totalStockholderEquity, last quarter 6.17b)
Debt / EBITDA = 0.37 (Net Debt 408.0m / EBITDA 1.09b)
Debt / FCF = 0.63 (Net Debt 408.0m / FCF TTM 643.0m)
Total Stockholder Equity = 6.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.72% (Net Income 510.0m / Total Assets 7.78b)
RoE = 8.38% (Net Income TTM 510.0m / Total Stockholder Equity 6.08b)
RoCE = 11.50% (EBIT 702.0m / Capital Employed (Equity 6.08b + L.T.Debt 17.0m))
RoIC = 8.38% (NOPAT 540.0m / Invested Capital 6.44b)
WACC = 7.91% (E(17.2b)/V(18.3b) * Re(8.10%) + D(1.11b)/V(18.3b) * Rd(6.38%) * (1-Tc(0.23)))
Discount Rate = 8.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 5.82 | Cagr: 0.04%
[DCF] Terminal Value 77.97% ; FCFF base≈535.8m ; Y1≈614.2m ; Y5≈903.9m
[DCF] Fair Price = 58.25 (EV 13.6b - Net Debt 408.0m = Equity 13.2b / Shares 226.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 72.40 | EPS CAGR: 35.86% | SUE: -0.59 | # QB: 0
Revenue Correlation: 97.57 | Revenue CAGR: 10.61% | SUE: -0.65 | # QB: 0
EPS current Quarter (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-09-30): EPS=2.39 | Chg30d=+2.92% | Revisions=+44% | GrowthEPS=+4.7% | GrowthRev=+6.5%
EPS next Year (2027-09-30): EPS=3.03 | Chg30d=-2.35% | Revisions=-22% | GrowthEPS=+26.8% | GrowthRev=+10.9%
[Analyst] Revisions Ratio: +13% (up=7, down=5)